EP1871887 - NOVEL hTMC PROMOTER AND VECTORS FOR THE TUMOR-SELECTIVE AND HIGH-EFFICIENT EXPRESSION OF CANCER THERAPEUTIC GENES [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 06.03.2009 Database last updated on 17.08.2024 | Most recent event Tooltip | 06.03.2009 | Application deemed to be withdrawn | published on 08.04.2009 [2009/15] | Applicant(s) | For all designated states Board of Regents, The University of Texas System 201 West 7th Street Austin, TX 78701 / US | [N/P] |
Former [2008/01] | For all designated states Board of Regents, The University of Texas System 201 West 7th Street Austin Texas 78701 / US | Inventor(s) | 01 /
FANG, Bingliang 9412 Sundown Drive Pearland, Texas 77584 / US | 02 /
ROTH, Jack, A. 6516 Brompton Road Houston, Texas 77005 / US | 03 /
JI, LinX. 2323 Cypress Run Dr. Sugar Land, TX 7747 / US | [2008/01] | Representative(s) | Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE | [N/P] |
Former [2008/35] | Vossius & Partner Siebertstrasse 3 81675 München / DE | ||
Former [2008/01] | Vossius & Partner Siebertstrasse 4 81675 München / DE | Application number, filing date | 06737660.8 | 09.03.2006 | [2008/01] | WO2006US08502 | Priority number, date | US20050659935P | 09.03.2005 Original published format: US 659935 P | [2008/01] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2006096815 | Date: | 14.09.2006 | Language: | EN | [2006/37] | Type: | A2 Application without search report | No.: | EP1871887 | Date: | 02.01.2008 | Language: | EN | The application published by WIPO in one of the EPO official languages on 14.09.2006 takes the place of the publication of the European patent application. | [2008/01] | Search report(s) | International search report - published on: | EP | 08.03.2007 | Classification | IPC: | C12N15/67 | [2008/01] | CPC: |
A61K48/0058 (EP,US);
C12N15/10 (KR);
A61P35/00 (EP);
A61P35/02 (EP);
C12N15/09 (KR);
C12N15/64 (KR);
C12N15/85 (EP,US);
C12N15/86 (EP,US);
C12N2710/10343 (EP,US);
C12N2830/008 (EP,US);
C12N2830/15 (EP,US);
C12N2830/60 (EP,US);
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2008/01] | Extension states | AL | Not yet paid | BA | Not yet paid | HR | Not yet paid | MK | Not yet paid | YU | Not yet paid | Title | German: | NEUARTIGER HTMC-PROMOTOR UND VEKTOREN ZUR TUMORSELEKTIVEN UND HOCHEFFIZIENTEN EXPRESSION KREBSTHERAPEUTISCHER GENE | [2008/01] | English: | NOVEL hTMC PROMOTER AND VECTORS FOR THE TUMOR-SELECTIVE AND HIGH-EFFICIENT EXPRESSION OF CANCER THERAPEUTIC GENES | [2008/01] | French: | PROMOTEUR HTMC ET VECTEURS DESTINES A L'EXPRESSION HAUTEMENT EFFICACE ET SELECTIVE POUR UNE TUMEUR DE GENES THERAPEUTIQUES CONTRE LE CANCER | [2008/01] | Entry into regional phase | 08.10.2007 | National basic fee paid | 08.10.2007 | Designation fee(s) paid | 08.10.2007 | Examination fee paid | Examination procedure | 12.03.2007 | Request for preliminary examination filed International Preliminary Examining Authority: EP | 08.10.2007 | Amendment by applicant (claims and/or description) | 08.10.2007 | Examination requested [2008/01] | 04.04.2008 | Despatch of a communication from the examining division (Time limit: M06) | 15.10.2008 | Application deemed to be withdrawn, date of legal effect [2009/15] | 20.11.2008 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2009/15] | Fees paid | Renewal fee | 08.10.2007 | Renewal fee patent year 03 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [PX] - DAVIS JJ ET AL, "Oncolysis and suppression of tumor growth by a GFP-expressing oncolytic adenovirus controlled by an hTERT and CMV hybrid promoter", CANCER GENE THERAPY, (20060217), pages 1 - 4, XP002406383 [PX] 1-117 * see the whole document * | [PX] - WU G. ET AL, "A novel synthetic hTERT-Mini_CMV chimera promoter-driven tumor-selective and high-efficiency expression of transgene for systemic cancer gene therapy", PROC. AMER. ASSOC. CANCER RES., (20050401), vol. 46, page 3358, XP002406384 [PX] 1-117 * see the whole document * | [X] - HAGSTROM J N ET AL, "Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, (20000415), vol. 95, no. 8, ISSN 0006-4971, pages 2536 - 2542, XP002223433 [X] 1,9,10 * see the whole document * | [X] - OMRULLEH S ET AL, "ACTIVITY OF A CHIMERIC PROMOTER WITH THE DOUBLED CAMV 35S ENHANCER ELEMENT IN PROTOPLAST-DERIVED CELLS AND TRANSGENIC PLANTS IN MAIZE", PLANT MOLECULAR BIOLOGY, SPRINGER, DORDRECHT, NL, (1993), vol. 21, no. 3, ISSN 0167-4412, pages 415 - 428, XP001024601 [X] 1 * see abstract * DOI: http://dx.doi.org/10.1007/BF00028800 | [X] - DIAZ R M ET AL, "Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma", JOURNAL OF VIROLOGY, (199801), vol. 72, no. 1, ISSN 0022-538X, pages 789 - 795, XP002406385 [X] 1 * see abstract * | [Y] - WANG J ET AL, "Enhanced suicide gene therapy by chimeric tumor-specific promoter based on HSF1 transcriptional regulation", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, (20030710), vol. 546, no. 2-3, ISSN 0014-5793, pages 315 - 320, XP004433665 [Y] 1-112 * see the whole document * DOI: http://dx.doi.org/10.1016/S0014-5793(03)00606-9 | [Y] - FUKAZAWA TAKUYA ET AL, "Development of a cancer-targeted tissue-specific promoter system.", CANCER RESEARCH, (20040101), vol. 64, no. 1, ISSN 0008-5472, pages 363 - 369, XP002406386 [Y] 1-112 * see the whole document * DOI: http://dx.doi.org/10.1158/0008-5472.CAN-03-2507 | [A] - AGHA-MOHAMMADI SIAMAK ET AL, "Regulatable systems: Applications in gene therapy and replicating viruses", JOURNAL OF CLINICAL INVESTIGATION, (200005), vol. 105, no. 9, ISSN 0021-9738, pages 1177 - 1183, XP002406387 DOI: http://dx.doi.org/10.1172/JCI10027 | [A] - MAJUMDAR A S ET AL, "The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters", GENE THERAPY, (200104), vol. 8, no. 7, ISSN 0969-7128, pages 568 - 578, XP002406388 DOI: http://dx.doi.org/10.1038/sj.gt.3301421 | [A] - HORIKAWA I ET AL, "CLONING AND CHARACTERIZATION OF THE PROMOTER REGION OF HUMAN TELOMERASE REVERSE TRANSCRIPTASE GENE", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, (19990215), vol. 59, ISSN 0008-5472, pages 826 - 830, XP002905138 |